These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7023592)

  • 1. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
    Christie JE; Shering A; Ferguson J; Glen AI
    Br J Psychiatry; 1981 Jan; 138():46-50. PubMed ID: 7023592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose arecoline infusions in Alzheimer's disease.
    Tariot PN; Cohen RM; Welkowitz JA; Sunderland T; Newhouse PA; Murphy DL; Weingartner H
    Arch Gen Psychiatry; 1988 Oct; 45(10):901-5. PubMed ID: 3048224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
    Raffaele KC; Berardi A; Asthana S; Morris P; Haxby JV; Soncrant TT
    Psychopharmacol Bull; 1991; 27(3):315-9. PubMed ID: 1775605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.
    Caltagirone C; Gainotti G; Masullo C
    Int J Neurosci; 1982 May; 16(3-4):247-9. PubMed ID: 7169287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
    Schwartz AS; Kohlstaedt EV
    Life Sci; 1986 Mar; 38(11):1021-8. PubMed ID: 3512944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physostigmine and its effect on six patients with dementia.
    Ashford JW; Soldinger S; Schaeffer J; Cochran L; Jarvik LF
    Am J Psychiatry; 1981 Jun; 138(6):829-30. PubMed ID: 7246817
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
    Asthana S; Raffaele KC; Berardi A; Greig NH; Haxby JV; Schapiro MB; Soncrant TT
    Alzheimer Dis Assoc Disord; 1995; 9(4):223-32. PubMed ID: 8749612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia.
    Caltagirone C; Albanese A; Gainotti G; Masullo C
    Int J Neurosci; 1983; 18(1-2):143-7. PubMed ID: 6840979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.
    Raffaele KC; Berardi A; Morris PP; Asthana S; Haxby JV; Schapiro MB; Rapoport SI; Soncrant TT
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):643-8. PubMed ID: 1956992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memory enhancement with oral physostigmine in Alzheimer's disease.
    N Engl J Med; 1983 Mar; 308(12):720-1. PubMed ID: 6338388
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
    Sano M; Bell K; Marder K; Stricks L; Stern Y; Mayeux R
    Clin Neuropharmacol; 1993 Feb; 16(1):61-9. PubMed ID: 8422658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral physostigmine in Alzheimer's disease.
    Stern Y; Sano M; Mayeux R
    Ann Neurol; 1987 Sep; 22(3):306-10. PubMed ID: 3674795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
    Sevush S; Guterman A; Villalon AV
    J Clin Psychiatry; 1991 Jul; 52(7):300-3. PubMed ID: 2071560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.